STAAR Surgical Gestion
Gestion contrôle des critères 2/4
Le PDG STAAR Surgical est Deborah Andrews, nommé en Mar2025, a un mandat de 1.25 ans. La rémunération annuelle totale est $ 2.58M, composée du salaire de 31.4% et des bonus 68.6%, y compris les actions et options de la société. détient directement 0.037% des actions de la société, d'une valeur de $ 546.28K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.2 ans et 2.3 ans.
Informations clés
Deborah Andrews
Directeur général
US$2.6m
Rémunération totale
| Pourcentage du salaire du PDG | 31.37% |
| Durée du mandat du directeur général | 1.3yrs |
| Propriété du PDG | 0.04% |
| Durée moyenne d'occupation des postes de direction | 2.2yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 2.3yrs |
Mises à jour récentes de la gestion
Recent updates
Article d’analyse • Jun 16
STAAR Surgical (STAA) Stock Could Be 4.4% Undervalued Despite Its Rich P S Multiple
Why STAAR Surgical Stock Is Drawing Attention Now STAAR Surgical (STAA) is back on investors’ radar after a volatile period, with the stock up over the past 3 months but down over the past month and past year. See our latest analysis for STAAR Surgical. Recent trading paints a mixed picture for STAAR Surgical, with the share price at $28.37 after a 90 day share price return of 58.94%, but a 5 year total shareholder return that declined 80.85%. This suggests near term momentum in contrast with...
Mise à jour du récit • Jun 16
STAA: China Rebound After Q1 Inflection Will Drive Future Re Rating
STAAR Surgical's analyst price target has been reset from $23.00 to about $39.24, with analysts pointing to stronger than expected Q1 results, signs of a China rebound, and updated long term assumptions on valuation multiples, even as management holds back on formal guidance. Analyst Commentary Recent Street research around STAAR Surgical has turned more constructive, with several bullish analysts lifting price targets and, in some cases, upgrading their ratings following the latest Q1 report.
Mise à jour du récit • Jun 02
STAA: China Recovery And Profitability Improvements Will Temper Prior Bearish Reassessment
The analyst price target for STAAR Surgical has shifted from $21.11 to $29.67 as analysts factor in Q1 results that were ahead of expectations, a stronger China contribution, and slightly higher modeled profitability, even as revenue growth assumptions and the projected future P/E are revised. Analyst Commentary Recent research shows a clear shift in sentiment around STAAR Surgical, with several firms lifting price targets following Q1 results that were ahead of expectations.Seeking Alpha • May 16
STAAR Surgical Q1 2026: Early Signs Of A Durable Turnaround
Summary STAAR Surgical Company delivered a robust 1Q26 beat, with revenue up 119% YoY to $93.5M and a swing to $5.2M net income. China’s market rebound, normalized inventory, and rapid EVO+ ICL adoption drove topline strength, while disciplined OpEx and manufacturing efficiency boosted margins to 73.6%. STAA is benefiting from a structural shift toward lens-based refractive surgery, gaining U.S. share despite a shrinking laser market and expanding its addressable market via FDA approval. Valuation remains elevated at 4.4x forward sales and 57x forward P/E, requiring sustained high-teens revenue growth and margin expansion to justify current multiples. Read the full article on Seeking Alpha
Mise à jour du récit • May 15
STAA: Limited China Visibility And Missing Guidance Will Restrain Future Share Performance
Analysts have raised the fair value estimate for STAAR Surgical stock from $13.00 to $16.00, citing higher price targets supported by stronger Q1 results, improving confidence in a China rebound, and updated models that reflect better profitability assumptions and a lower future P/E multiple. Analyst Commentary Street research on STAAR Surgical has turned more constructive around the recent Q1 update, but the tone is not uniformly positive.Mise à jour du récit • Apr 20
STAA: China Uncertainty And Leadership Transition Will Drive Bearish Reassessment
STAAR Surgical's updated fair value estimate shifts from $26.56 to $21.11 as analysts factor in revised Street targets. These include recent cuts to around $18 to $22 that reflect questions on China exposure and mixed near term visibility, despite some more supportive views emerging.Mise à jour du récit • Apr 06
STAA: China Clarity And Post Alcon Reset Will Drive Future Re Rating
Analysts have trimmed price targets on STAAR Surgical to a range around $18 to $22, with a consensus reset of approximately $23.00, reflecting ongoing questions about China exposure, recent Q4 volatility, and limited near term visibility following the rejected Alcon deal. Analyst Commentary Recent Street commentary around STAAR Surgical centers on uncertainty, but there are pockets of optimism that readers should weigh alongside the more cautious views.Mise à jour du récit • Mar 23
STAA: Ongoing China Uncertainty And Governance Turmoil Will Pressure Shares
Analysts have reduced the consolidated price target for STAAR Surgical to $22 from $28, reflecting lower assumptions for revenue growth and profit margins, a much higher future P/E multiple, and ongoing uncertainty around China and the company’s broader path forward. Analyst Commentary Recent Street research on STAAR Surgical points to a cautious tone, with multiple bearish analysts cutting price targets and reiterating neutral or underweight stances.Mise à jour du récit • Mar 09
STAA: China Clarity And Post Alcon Reset Will Shape Future Upside Potential
Narrative Update on STAAR Surgical Our analyst price target for STAAR Surgical has been revised from $30.75 to $23.00 as analysts factor in recent target cuts, ongoing uncertainty around China and limited near term visibility highlighted in the latest research. Analyst Commentary Recent research on STAAR Surgical has leaned cautious, with multiple firms revising price targets lower and emphasizing uncertainty around the company’s outlook, particularly related to China and the failed Alcon transaction.Mise à jour du récit • Feb 23
STAA: Post Deal Rejection Concerns Will Keep Shares Under Pressure
Analysts have reduced their average price targets on STAAR Surgical by high single digit dollar amounts to around $13.00. This reflects more cautious views on profit margins and valuation multiples after the failed Alcon deal and a series of Neutral and Underweight ratings.Mise à jour du récit • Feb 08
STAA: Post Deal Collapse Uncertainty Will Pressure Shares Until Leadership Path Clears
Narrative Update on STAAR Surgical The analyst price target for STAAR Surgical has been reduced by US$8.75 following a neutral initiation, an Underweight resumption, and cautious commentary from several firms who highlight limited investor appetite until there is greater clarity on the company after the failed Alcon transaction. Analyst Commentary Recent Street research around STAAR Surgical has leaned cautious, with several firms highlighting valuation, execution, and growth risks following the failed Alcon transaction and the subsequent shareholder vote.Mise à jour du récit • Jan 25
STAA: Post Alcon Deal Collapse And CEO Exit Will Cap Near Term Upside
Analysts have trimmed their fair value estimate for STAAR Surgical from US$17.41 to US$13.00, reflecting lower assumed revenue growth and a reduced future P/E multiple, alongside cautious commentary around limited buyer interest and uncertainty following the failed Alcon deal. Analyst Commentary Recent Street research has tilted clearly cautious, with several bearish analysts highlighting valuation pressure, deal uncertainty, and limited near term visibility on the business.Mise à jour du récit • Jan 10
STAA: Failed Alcon Deal And Takeover Optionality Will Reshape Future Appeal
Analysts have lifted their fair value estimate for STAAR Surgical shares from US$28.00 to US$30.75, reflecting updated assumptions on growth, margins and future P/E multiples after recent debate over the failed Alcon deal and the limited near term appeal highlighted in recent research. Analyst Commentary Recent research has centered on the failed Alcon transaction, shareholder pushback on deal terms, and the limited near term appeal cited by several firms.Mise à jour du récit • Dec 26
STAA: Amended Alcon Deal And Activist Push Will Drive Bullish Upside
Analysts have nudged their fair value estimate for STAAR Surgical higher from approximately $25.88 to $26.56. This reflects modestly stronger growth and margin expectations while acknowledging that any amended Alcon deal is unlikely to include a materially higher bid.Mise à jour du récit • Dec 12
STAA: Merger Uncertainty Will Restrain Upside Despite Higher All-Cash Offer
Analysts have modestly raised their price target on STAAR Surgical from $16.00 to approximately $17.41 per share, citing slightly improved assumptions for long term revenue growth, profitability, and future valuation multiples, while they continue to monitor ongoing merger term discussions with Alcon. Analyst Commentary Bearish analysts highlight that the postponed shareholder meeting reinforces uncertainty around the timing and ultimate outcome of the proposed acquisition, which in turn clouds visibility on STAAR Surgical's standalone valuation.Mise à jour du récit • Nov 28
STAA: Amended Merger Terms And Shareholder Opposition Will Guide Share Price Direction
Analysts have maintained their price target for STAAR Surgical at $25.88, citing limited expected upside due to ongoing merger negotiations and continued uncertainty regarding the acquisition terms. Analyst Commentary Market commentary surrounding STAAR Surgical’s ongoing merger negotiations reflects mixed analyst sentiment, with both cautious and optimistic perspectives regarding the company’s prospects and valuation.Mise à jour du récit • Nov 12
STAA: Merger Discussions and Shareholder Opposition Will Shape Path Forward
Analysts have revised STAAR Surgical's price target downward to $16 from previous levels. They cite ongoing shareholder opposition to the proposed merger terms and uncertainty about a potential acquisition price.Mise à jour du récit • Oct 29
Board Opposition And Postponed Vote Will Shape Acquisition Outcome In 2025
Analysts have raised their average price target for STAAR Surgical from $20 to $28 per share. They cite the strategic rationale and valuation of the proposed acquisition by Alcon as key drivers for the upward revision.Mise à jour du récit • Oct 15
Introduction Of EVO+ Will Open Market Opportunities In 2025
Analysts have raised their price target for STAAR Surgical from $24.63 to $25.88. This reflects the impact of an increased acquisition offer and the perceived strategic value from Alcon's proposed purchase.Mise à jour du récit • Aug 20
Introduction Of EVO+ Will Open Market Opportunities In 2025
Analysts have raised their price targets for STAAR Surgical primarily to reflect the proposed $28/share acquisition by Alcon, which sets a new benchmark valuation and limits further upside, resulting in a new consensus fair value of $24.14. Analyst Commentary Bullish analysts raised their price targets to align with the proposed $28/share acquisition price by Alcon.Mise à jour du récit • Aug 06
Introduction Of EVO+ Will Open Market Opportunities In 2025
Driven by a significant improvement in net profit margin despite a higher discount rate, STAAR Surgical's consensus price target has increased from $19.20 to $22.11. What's in the News Alcon Inc.Article d’analyse • Jul 04
Getting In Cheap On STAAR Surgical Company (NASDAQ:STAA) Might Be Difficult
There wouldn't be many who think STAAR Surgical Company's ( NASDAQ:STAA ) price-to-sales (or "P/S") ratio of 3.2x is...Article d’analyse • Apr 05
Is STAAR Surgical Company (NASDAQ:STAA) Trading At A 37% Discount?
Key Insights The projected fair value for STAAR Surgical is US$25.07 based on 2 Stage Free Cash Flow to Equity Current...Article d’analyse • Feb 14
Why Investors Shouldn't Be Surprised By STAAR Surgical Company's (NASDAQ:STAA) 26% Share Price Plunge
Unfortunately for some shareholders, the STAAR Surgical Company ( NASDAQ:STAA ) share price has dived 26% in the last...Seeking Alpha • Feb 12
STAAR Surgical Q4: Ongoing Challenges In China Masks Healthy Growth Elsewhere
Summary STAAR Surgical's Q4 results were severely impacted by lower demand and high inventory levels in China. Global growth ex-China was 17% in Q4 and is expected to remain strong at 12% for FY25, with US growth of close to 15%. Cash burn is expected to be significant, but the company is financially healthy, having $232 million in cash and no debt on its balance sheet. Following the post-earnings drop, shares are cheaply valued given the long growth runway ahead, which leads me to maintain my Buy rating on STAA stock. Read the full article on Seeking AlphaSeeking Alpha • Jan 31
STAAR Surgical: Growth Story Remains Intact Despite Some Challenges
Summary Shares have been under pressure lately due to weak demand from China, which is by far the company’s largest market. The market opportunity in the US remains large, and management is investing heavily to tap into it. I have modest expectations for overall growth in FY25 of 9%, with markets excluding China growing significantly faster. The FCF margin in FY25 is expected to be around 8.3% given the ongoing growth investments, while I expect that it can reach close to 20% in the long term. I am assigning a Buy rating on the stock with a target priceof $35, implying an upside of over 45%. Read the full article on Seeking AlphaArticle d’analyse • Nov 29
STAAR Surgical Company's (NASDAQ:STAA) Earnings Haven't Escaped The Attention Of Investors
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...Article d’analyse • Oct 24
Return Trends At STAAR Surgical (NASDAQ:STAA) Aren't Appealing
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...
Nouveau récit • Sep 13
EVO ICL Technology Transforms Vision Care, Securing Major Growth And Market Share Expansion
STAAR Surgical's record sales and expansion in the diopter curve indicate strong global adoption of EVO ICL technology and potential for increased market share.Seeking Alpha • Sep 05
STAAR Surgical: Expecting A Re-Acceleration In Growth As Investments Materialize
Summary STAAR Surgical shares are down more than 15% since Q2 earnings, despite management raising full-year revenue guidance. Investments in the US market appear to be yielding promising results, as sales were up 25% year over year. According to my estimates, the company is on track to meet the low end of its 2026 financial targets. I have a price target of $46 by 2026, which represents an attractive upside from today’s level. Read the full article on Seeking AlphaArticle d’analyse • Aug 10
Results: STAAR Surgical Company Exceeded Expectations And The Consensus Has Updated Its Estimates
STAAR Surgical Company ( NASDAQ:STAA ) investors will be delighted, with the company turning in some strong numbers...Article d’analyse • Aug 05
STAAR Surgical Company's (NASDAQ:STAA) Popularity With Investors Is Clear
When close to half the companies in the Medical Equipment industry in the United States have price-to-sales ratios (or...Article d’analyse • Jul 12
The Returns At STAAR Surgical (NASDAQ:STAA) Aren't Growing
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Article d’analyse • May 27
Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?
While STAAR Surgical Company ( NASDAQ:STAA ) might not have the largest market cap around , it received a lot of...Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Apr 03 2026 | n/a | n/a | -US$21m |
| Jan 02 2026 | US$3m | US$810k | -US$80m |
| Sep 26 2025 | n/a | n/a | -US$96m |
| Jun 27 2025 | n/a | n/a | -US$95m |
| Mar 28 2025 | n/a | n/a | -US$71m |
| Dec 27 2024 | n/a | n/a | -US$20m |
| Sep 27 2024 | n/a | n/a | US$22m |
| Jun 28 2024 | n/a | n/a | US$17m |
| Mar 29 2024 | n/a | n/a | US$15m |
| Dec 29 2023 | n/a | n/a | US$21m |
| Sep 29 2023 | n/a | n/a | US$20m |
| Jun 30 2023 | n/a | n/a | US$26m |
| Mar 31 2023 | n/a | n/a | US$33m |
| Dec 30 2022 | n/a | n/a | US$40m |
| Sep 30 2022 | n/a | n/a | US$38m |
| Jul 01 2022 | n/a | n/a | US$34m |
| Apr 01 2022 | n/a | n/a | US$29m |
| Dec 31 2021 | n/a | n/a | US$28m |
| Oct 01 2021 | n/a | n/a | US$23m |
| Jul 02 2021 | n/a | n/a | US$21m |
| Apr 02 2021 | n/a | n/a | US$11m |
| Jan 01 2021 | US$755k | US$366k | US$6m |
| Oct 02 2020 | n/a | n/a | US$9m |
| Jul 03 2020 | n/a | n/a | US$7m |
| Apr 03 2020 | n/a | n/a | US$13m |
| Jan 03 2020 | US$854k | US$351k | US$14m |
Rémunération vs marché: La rémunération totale de Deborah ($USD 2.58M ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 5.19M ).
Rémunération et revenus: La rémunération de Deborah a augmenté alors que l'entreprise n'est pas rentable.
PDG
Deborah Andrews (69 yo)
1.3yrs
Titularisation
US$2,582,411
Compensation
Ms. Deborah J. Andrews is Chief Financial Officer of STAAR Surgical Company since June 25, 2025 and is its Interim Co-Chief Executive Officer since February 1, 2026. She was Interim Chief Financial Officer...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Interim Co-CEO & CFO | 1.3yrs | US$2.58m | 0.037% $ 546.3k | |
| Interim Co-CEO | 3.2yrs | US$4.44m | 0.17% $ 2.4m | |
| Chief Development Officer | 3.2yrs | US$2.70m | 0.086% $ 1.3m | |
| Director of Investor Relations | no data | pas de données | pas de données | |
| VP, Deputy General Counsel and Chief Compliance & Privacy Officer | less than a year | pas de données | pas de données | |
| Chief Medical Officer | 8.7yrs | US$2.48m | pas de données | |
| Senior Vice President of Global E2E Supply Chain | 1yr | pas de données | pas de données |
2.2yrs
Durée moyenne de l'emploi
63yo
Âge moyen
Gestion expérimentée: L'équipe de direction de STAA est considérée comme expérimentée (ancienneté moyenne 2.2 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Independent Director | 11.8yrs | US$254.79k | 0.022% $ 326.8k | |
| Independent Chairman of the Board | less than a year | pas de données | 0.052% $ 758.6k | |
| Independent Director | 2.5yrs | US$448.57k | 0.016% $ 237.3k | |
| Independent Director | less than a year | pas de données | 0.044% $ 648.2k | |
| Member of Optometric Advisory Council | 17.6yrs | pas de données | pas de données | |
| Independent Director | 2.3yrs | US$243.39k | 0.019% $ 279.7k | |
| Independent Director | 2.3yrs | US$1.54m | 0.15% $ 2.3m | |
| Independent Director | less than a year | pas de données | 0% $ 0 |
2.3yrs
Durée moyenne de l'emploi
60yo
Âge moyen
Conseil d'administration expérimenté: Le conseil d'administration de la STAA n'est pas considéré comme expérimenté ( 2.3 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/28 03:47 |
| Cours de l'action en fin de journée | 2026/06/26 00:00 |
| Les revenus | 2026/04/03 |
| Revenus annuels | 2026/01/02 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
STAAR Surgical Company est couverte par 20 analystes. 11 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Michael Gorman | BTIG |
| William Plovanic | Canaccord Genuity |
| John Young | Canaccord Genuity |